1 / 11

Erythropoietin Drugs Market - The Industry Set to grow positively

Erythropoietin Drugs Market is Expected to Reach $11.9 Billion by 2020. Visit at: https://www.alliedmarketresearch.com/erythropoietin-market<br><br>A new report by Allied Market Research titled, "Global Erythropoietin (EPO) Drugs Market (Type, Application and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013-2020", forecasts the Global EPO market to reach $11.9 billion by 2020, with promising CAGR of 9.7% from 2014 to 2020. Darbepoetin alfa is fastest growing drug class at a CAGR of 12.9% during the forecast period, owing to its high potency and minimal side-effects.<br>

bethzhurst
Télécharger la présentation

Erythropoietin Drugs Market - The Industry Set to grow positively

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Erythropoietin Drugs Market Forecast 2013 - 2020 Published Date: 14 January 2015 No. of pages : 115

  2. Introduction to Erythropoietin Drugs Market Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetinalfa, epoetin beta, darbepoetinalfa, epoetin omega, and epoetin delta among the others. The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars. The global EPO drugs market would reach $11.9 billion by 2020, registering CAGR of 9.7% during 2014-2020. Amongst all synthetic erythropoietin products, Epoetinalfa and its advance version, Darbepoetinalfa, are the most popular drugs. Epoetinalfa and Darbepoetinalfa collectively accounted for ~80% of total EPO drugs market revenue. Amgen Inc. was first company to innovate Epoetinalfa and Darbepoetinalfa that are branded/patented as Epogen and Aranesp respectively. However, expiration of Amgen’s patent for Epogen has aided manufacturers of biosimilars to enter the EPO drugs market. Based on the applications, the global EPO drugs market is segmented into anemia associated with End Stage Renal Diseases (ESRD), cancer chemotherapy and, antiretroviral treatment (ART).  Current research is focused toward expanding the applications of EPO drugs in other disease conditions such as neural diseases and wound healing.

  3. Introduction Scope of the Report Key Benefits Key Audiences

  4. KEY BENEFITS • An in-depth analysis of current research and clinical developments within EPO drugs market is provided with key market dynamic factors that helps in understanding the behavior of market  • The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize on • Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework • Comprehensive analysis of all geographic regions are provided that helps in determining the prevailing opportunities in these geographies • Key market players within the EPO drugs market are profiled in the report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global EPO drugs market 

  5. Table of Contents INTRODUCTION EXECUTIVE SUMMARY MARKET OVERVIEW GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY COMPANY PROFILES

  6. Global Erythropoietin Drugs Market Overview Market Definition & Scope Evolution of Erythropoietin drugs Erythropoietin Omega and Delta: pruned R&D pipeline drugs Ethical considerations of erythropoietin drugs Key findings Value Chain Analysis Key market player positioning (2014) Product positioning for patented products (2014) Clinical trials for EPO drug in neural diseases and wound healing Competitive Intelligence on top three leaders (Amgen, J&J and Roche) Market share analysis, 2013 Market dynamics

  7. Global Erythropoietin Market By Products

  8. Global Erythropoietin Market By Applications

  9. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY GEOGRAPHY  North America, Europe, Asia Pacific, LAMEA

  10. Company Profiles Amgen Inc. Johnson and Johnson Roche  Hospira LG Life Sciences Ltd. Biocon IntasPharmaceuticals Teva Pharmaceutical Industries Ltd. Ranbaxy Laboratories Ltd. Celltrion, Inc

  11. Thank You! For More Details Visit us at http://www.alliedmarketresearch.com/erythropoietin-market Follow Us On

More Related